Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial

Autor: Yao Liu, Brennan Greene, Jacob W. Brubaker, Kevin Y. Jong, Scott Corin, Justus W. Thomas, Vickas Khemsara, Ehsan Sadri, Thomas D. LoBue, William J. Flynn, Navin H Tekwani, William C. Christie, Farrell C. Tyson, Matthew J. Swanic, Damien F. Goldberg, Sanjay Asrani, Ranjan P. Malhotra, Matthew G. McMenemy, Karen L. Klugo, Lawrence B. Katzen, John F. Kozlovsky, Bernard R. Perez, Alan L. Robin, Stephen Vold, John Nicolau, Mihir Parikh, Dale W Usner, Ettaleah C. Bluestein, John S. Cohen, Stacey L. Ackerman, Thomas T. Henderson, Kundandeep Nagi, Nicole M. Collins, Jodi Ian Luchs, Robert M. Saltzmann, Andrew Mays, Jay Mulaney, Jody R. Piltz-Seymour, Sayoko E. Moroi, Fiaz Zaman, Savak Teymoorian, Eran Duzman, Howard I. Schenker, Casey Kopczynski, Gary Jerkins, Eugene B. McLaurin, Mark J. Weiss, Kent Bashford, Todd Daynes, Joseph P. Gira, Brian E. Flowers, Theresa Heah, Scott B. Han, Donna Leonardo, Michael Depenbusch, Janet B. Serle, Raymond Fong, James D. Boyce, James D. Branch, Louis M. Alpern, Lee S. Peplinski, Jay R. Patel, El-Roy Dixon, Richard A Lewis, Satish Modi

Publikováno v: American journal of ophthalmology. 207

To compare the ocular hypotensive efficacy and safety of a fixed-dose combination (FDC) of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost.Three-month primary endpoint analysis of a randomized, double

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbd758b3a0a0f544965375ad584fb731
https://pubmed.ncbi.nlm.nih.gov/31229466